Fusion Pharmaceuticals Statistics
Share Statistics
Fusion Pharmaceuticals has 85.06M
shares outstanding. The number of shares has increased by 0%
in one year.
| Shares Outstanding | 85.06M |
| Shares Change (YoY) | 0% |
| Shares Change (QoQ) | 0% |
| Owned by Institutions (%) | n/a |
| Shares Floating | n/a |
| Failed to Deliver (FTD) Shares | 600 |
| FTD / Avg. Volume | 0.03% |
Short Selling Information
| Short Interest | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Valuation Ratios
The PE ratio is -6.64 and the forward
PE ratio is null.
Fusion Pharmaceuticals's PEG ratio is
0.24.
| PE Ratio | -6.64 |
| Forward PE | n/a |
| PS Ratio | 304.9 |
| Forward PS | n/a |
| PB Ratio | 2.83 |
| P/FCF Ratio | -7.36 |
| PEG Ratio | 0.24 |
Financial Ratio HistoryEnterprise Valuation
Fusion Pharmaceuticals has an Enterprise Value (EV) of 618.94M.
| EV / Sales | 299.29 |
| EV / EBITDA | -6.32 |
| EV / EBIT | -7.57 |
| EV / FCF | -7.22 |
Financial Position
The company has a current ratio of 15.01,
with a Debt / Equity ratio of 0.18.
| Current Ratio | 15.01 |
| Quick Ratio | 15.01 |
| Debt / Equity | 0.18 |
| Debt / EBITDA | -0.51 |
| Debt / FCF | -0.59 |
| Interest Coverage | -19.21 |
Financial Efficiency
Return on Equity is -42.65% and Return on Invested Capital is -38.28%.
| Return on Equity | -42.65% |
| Return on Assets | -33.2% |
| Return on Invested Capital | -38.28% |
| Revenue Per Employee | $20,475.25 |
| Profits Per Employee | $-939,574.26 |
| Employee Count | 101 |
| Asset Turnover | 0.01 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | 787K |
| Effective Tax Rate | -0.84% |
Stock Price Statistics
The stock price has increased by 0.7% in the
last 52 weeks. The beta is -0.69, so Fusion Pharmaceuticals's
price volatility has been lower than the market average.
| Beta | -0.69 |
| 52-Week Price Change | 0.7% |
| 50-Day Moving Average | 21.4 |
| 200-Day Moving Average | 10.51 |
| Relative Strength Index (RSI) | 69.06 |
| Average Volume (20 Days) | 1,965,984 |
Income Statement
In the last 12 months, Fusion Pharmaceuticals had revenue of 2.07M
and earned -94.9M
in profits. Earnings per share was -1.45.
| Revenue | 2.07M |
| Gross Profit | 723K |
| Operating Income | -99.23M |
| Net Income | -94.9M |
| EBITDA | -97.89M |
| EBIT | -88.94M |
| Earnings Per Share (EPS) | -1.45 |
Full Income StatementBalance Sheet
The company has 61.92M in cash and 50.33M in
debt, giving a net cash position of 11.59M.
| Cash & Cash Equivalents | 61.92M |
| Total Debt | 50.33M |
| Net Cash | 11.59M |
| Retained Earnings | -376.76M |
| Total Assets | 323.81M |
| Working Capital | 200.16M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -81.8M
and capital expenditures -3.89M, giving a free cash flow of -85.69M.
| Operating Cash Flow | -81.8M |
| Capital Expenditures | -3.89M |
| Free Cash Flow | -85.69M |
| FCF Per Share | -1.31 |
Full Cash Flow StatementMargins
Gross margin is 34.96%, with operating and profit margins of -4798.45% and -4588.83%.
| Gross Margin | 34.96% |
| Operating Margin | -4798.45% |
| Pretax Margin | -4550.77% |
| Profit Margin | -4588.83% |
| EBITDA Margin | -4733.41% |
| EBIT Margin | -4798.45% |
| FCF Margin | -4143.71% |
